190 filings
Page 2 of 10
8-K
umo2a1
22 Mar 23
Other Events
4:10pm
8-K
mfelkyu7n4j8el1ai
10 Feb 23
Termination of a Material Definitive Agreement
4:31pm
8-K
fqk8krrxuzc
7 Feb 23
Tenax Therapeutics Announces Pricing of Approximately $15.6 Million Public Offering
4:31pm
8-K
suk4sojb8 jtbgl4ffon
1 Feb 23
Patent is expected to provide additional intellectual property protection until 2040
4:46pm
8-K
8aofcc8
20 Jan 23
Other Events
4:10pm
8-K
wz1d3yjeryp4uxbbf
4 Jan 23
Tenax Therapeutics Announces Reverse Stock Split
5:05pm
8-K
sjdbu nwwxe
11 Oct 22
Positive Data Presented at HFSA Annual Meeting Demonstrate Effects of Oral
8:31am
8-K
fdzotgd53z7ud4ndgj
20 Sep 22
Other Events
4:30pm
8-K
aauhmshdn
15 Sep 22
Tenax Therapeutics Announces the Evaluation of Strategic Alternatives
9:00am
8-K
yhxvhk9jwdma5kr3
18 Aug 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:30pm
8-K
gaeakachbw
16 Jun 22
Entry into a Material Definitive Agreement
4:35pm
8-K
8nad7abmau
10 Jun 22
Departure of Directors or Certain Officers
4:31pm
8-K
o5r5z33uxqi8r ts4
23 May 22
Tenax Therapeutics Announces Successful
4:32pm
8-K
io4kfc55bkv9o 2mvt
20 May 22
Tenax Therapeutics Announces Certain Securities and Nasdaq Disclosures
4:30pm
8-K
ngn514 jlb
24 Mar 22
Other Events
8:15am
8-K
1e2xr0d0edsv
18 Feb 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:33pm
8-K
2mjzwzt vr3u
31 Jan 22
Tenax Therapeutics Appoints Robyn Hunter to the Board of Directors
4:29pm
8-K
6a7cvy2p5ym19qs
28 Jan 22
Entry into a Material Definitive Agreement
4:16pm
8-K
g8imlp1q3l m5
24 Jan 22
TENAX THERAPEUTICS January 2022 I Corporate Presentation www.tenaxthera.com NASDAQ TENX
4:16pm
8-K
bv7jyvg34gqk82dk
12 Jan 22
Tenax Therapeutics Granted U.S. Patent for the Subcutaneous
4:53pm